Teva is exploring options for filing a long-acting injectable version of risperidone for subcutaneous administration in the US, following positive trial results for the product that it is co-developing with MedinCell.
The TV-46000/mdc-IRM risperidone extended-release injectable suspension for subcutaneous use is intended as a monthly or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?